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Purpose: To report a case of Essure microinsert abdominal migration and literature review.
Methods: A 41-year-old woman was counseled to undergo Essure sterilization. The procedure 
was hampered by the presence of endometrial cavity adhesions, obscuring left tubal ostium. By 
using microscissors the adhesions were progressively lysed. Since the procedure had become 
very painful, the patient required general anesthesia. Once adhesion lysis was completed, the 
tubal ostium was well visible. Both devices were then easily introduced into the fallopian tubes. 
At the end of the procedure, five coils were visible on the right side and five coils on the left 
side, as recommended.
Results: The 3-month hysterosalpingogram follow-up suspected abdominal migration of the left 
device. Laparoscopy confirmed the device displacement in the left lower abdominal quadrant. 
Both fallopian tubes and the uterus appeared normal. No signs of perforation were detected. The 
device was embedded into the omentum, but it was easily removed. Bilateral tubal sterilization 
was performed by bipolar coagulation.
Conclusion: There are only 13 cases, including the present, of Essure abdominal migration in 
the literature. In most cases, abdominal displacement of the microinsert is asymptomatic and 
does not induce tissue damage. However, in some cases, it may cause a severe adverse event, 
requiring major surgery. Therefore, removal of the migrated device should be performed as soon 
as possible. Moreover, during presterilization counseling, the patient should also be correctly 
informed about the risk of this rare but relevant complication, as well as about the surgical 
interventions that could be required to solve it.
Keywords: abdominal migration, Essure, hysteroscopic sterilization, hysteroscopy, tubal 
sterilization
Introduction
The Essure system was approved in November 2001 by the European Health Office and 
in November 2002 by the US Food and Drug Administration (FDA). According to the 
manufacturer, about 750,000 women have had it implanted to date. Many studies have 
shown that Essure is a safe and highly effective method of sterilization with a good 
patient compliance.1 However, with the increase in its use, it has become clear that this 
method is not without complications, which, in some cases, can also require a major 
surgical procedure.2 Abdominal migration of the device is a very rare complication 
of Essure sterilization. A recent analysis of adverse events reported in the Manufac-
turer and User Facility Device Experience (MAUDE) database (a system mandated 
by the FDA for postmarket surveillance) includes 90 cases of uterine perforation and 
33 cases of microinsert malposition.3 However, no percentage of abdominal device 
migration is provided. Therefore, the actual risk of Essure abdominal migration is 
not known. There are very few cases reported in the literature and only some of these 
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are fully described. There was no uniform management of 
this complication, especially in asymptomatic patients. The 
aim of this article is to report a case of abdominal Essure 
migration and a review of the literature. The management 
of abdominal Essure migration is also discussed.
Case report
A 41-year-old woman, gravida 3, para 2, was counseled to 
undergo Essure sterilization. She had dyslipidemia and her 
body mass index was 25. Four years earlier she had suffered 
a stroke while using oral contraceptives. This event caused 
persistent mild neurological deficits. Cycles were regular and 
gynecological examination was normal. The hysteroscopic 
sterilization was hampered by the presence of endometrial 
cavity adhesions obscuring left tubal ostium. By using 
microscissors the adhesions were progressively lysed. Since 
the procedure had become very painful, the patient required 
general anesthesia. Once adhesion lysis was completed, 
the tubal ostium was well visible. Both devices were then 
easily introduced into the fallopian tubes. At the end of the 
procedure, five coils were visible on the right side and five 
coils on the left side, as recommended. The procedure was 
completed in 25 minutes. The same day the patient was 
discharged and she was doing well. 
During the following weeks, the patient did not complain 
of any symptoms. The 3-month hysterosalpingogram (HSG) 
follow-up showed that the right tube was occluded and the 
device was correctly placed (Figure 1). Conversely, the left 
tube was patent and the device was abnormally located in the 
left side of the pelvis, away from the tubal distal extremity. 
Although the patient was asymptomatic, she was counseled 
to undergo laparoscopy in order to remove the device and 
complete tubal sterilization. Laparoscopy showed that the 
left device was displaced in the left lower quadrant, embed-
ded into the omentum, without signs of inflammation or 
adhesions. The uterus and the fallopian tubes appeared 
normal, and no signs of perforation were detected. The 
device was easily removed by blunt and sharp dissection. 
Bilateral tubal sterilization was subsequently performed 
by bipolar coagulation. The patient’s postoperative course 
was uneventful.
Discussion
Essure abdominal displacement is a very rare complica-
tion of hysteroscopic sterilization. The real frequency of 
this event is difficult to estimate because not all cases are   
reported. We reviewed the literature by searching in the 
Ovid/MEDLINE, PubMed, Scopus, and Google Scholar 
databases for all the articles published from January 2002 
to December 2013. The following terms were used: “Essure 
microinsert”, “hysteroscopic sterilization”, “transcervical 
sterilization”, “tubal occlusion”, “perforation”, “abdominal 
migration”, and “complication”. We also reviewed all the 
references cited in the papers. The cases of tubal or uterus 
perforation, or “perforation” without other specification, 
in which abdominal displacement of the device was not 
explicitly mentioned, were excluded. All types of studies, 
including case reports, case series, controlled clinical trials, 
and randomized controlled trials, were considered. There 
were no language restrictions. Animal studies were excluded. 
The literature search identified 59 articles, 51 of which were 
excluded, leaving eight articles describing 12 cases of Essure 
abdominal migration for final analysis (Figure 2).4–11
To the best of our knowledge, the case that we have 
observed is the 13th reported case in literature. It shows 
some peculiarities in respect to the other cases reported. 
Although the procedure was complicated and a tubal per-
foration might have been supposed, after the procedure and 
in the following period, the patient remained asymptomatic 
and the laparoscopy bore no evidence of uterine or tubal 
injury. Moreover, even if the microinsert was completely 
embedded into the omentum, no signs of inflammation or 
adhesions were observed.
Table 1 summarizes all reported cases of Essure abdomi-
nal migration and allows the drawing of some suggestions 
to manage this rare complication. 
Figure 1 Hysterosalpingogram.
Notes: Hysterosalpingogram showing tubal occlusion on the right side with correct 
location of the device (right arrow) and a patent tube on the left side. The left device 
is abnormally positioned (left arrow).Therapeutics and Clinical Risk Management 2014:10 submit your manuscript | www.dovepress.com
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Figure 2 Flow diagram for study selection.
Abbreviation: MaUDe, Manufacturer and User Facility Device experience.
Studies identified through
Ovid/MEDLINE, PubMed, Scopus
and Google Scholar databases
(n=58)
Additional studies identified
through other sources
(MAUDE database) (n=1)
Studies identified
(n=59)
Studies screened
(n=59)
Studies excluded
(n=45)
2 abstracts of scientific meetings
subsequently published;
3 as a more updated dataset
were subsequently published;
1 as significant overlap with
another included publication
Studies excluded,
with reasons (n=6)
Studies assessed
for eligibility
(n=14)
Studies included in
qualitative synthesis
(n=8)
Various factors may influence the risk of hysteroscopic 
sterilization complication among which the operator’s 
experience and the anatomical anomalies represent the most 
relevant ones.1,2 The operator’s experience significantly influ-
ences the rate of Essure migration. In fact, in the initial series, 
the reported rate is approximately 1%–2%,5 whereas, in large 
series, including long-term experience, the rate is very low.9 
Among more than 4,300 cases observed in 7 years, Povedano 
et al9 report a rate of only 0.04%. Anatomical impediments 
such as ostium stenosis, occlusion, no visible ostium/scarring, 
and extremely lateral/tortuous tubes, as well as uterine 
pathology (polyps, adhesions), may make the placement of 
Essure difficult.1,2 In the present review, in three out of eight 
patients, the device displacement might be explained by the 
presence of laterally sited ostia,5 by tubal resistance,7 or by 
endometrial cavity adhesions (present case). On the contrary, 
in five out of eight cases, abdominal migration occurred after 
an uneventful procedure.5,6,8,10,11 
A further risk factor of complication may be represented 
by general anesthesia, as it may, in fact, hide the pain due to 
tubal perforation. Unfortunately, except for our case, in the 
other reviewed cases, the analgesic or anesthetic protocol 
used was not specified. However, the abdominal migration 
was asymptomatic in most of the reported cases.5,6,8,10,11 Only 
our patient required general anesthesia due to unbearable pain 
during the procedure, whereas in the first case described by 
Vellayan et al5 the pain that occurred during the procedure 
settled spontaneously. In the 80% of cases reviewed in 
this paper, the displacement of the device was diagnosed 
at 3-month follow-up HSG (Table 1). In these cases, the 
postoperative course was uncomplicated, except for in the 
first patient observed by Vellayan et al5 who 6 days after Therapeutics and Clinical Risk Management 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
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the procedure complained of pain, which was settled after 
antibiotic administration. In two cases the diagnosis was 
made 1 month after an uncomplicated procedure because 
the patients complained of rapidly worsening abdominal 
symptomatology.8,11 In one of these cases, a small bowel 
obstruction was diagnosed by laparoscopy.8 Lysis of adhe-
sions, removal of the Essure microinsert, appendectomy, and 
left salpingectomy were performed, leading to the resolution 
of the symptoms.8 In the second case, due to nausea, vomit-
ing, abdominal pain, and X-ray findings, the patient under-
went a laparotomy.11 A microinsert had transversed across the 
mesentery and ensnared a loop of the terminal ileum, causing 
strangulation and perforation of the bowel wall.11 Thus, the 
migrated device was removed and an ileocecal resection was 
performed with a side-to-side ileocolostomy.11
As shown in Table 1, in asymptomatic patients almost 
all authors decided to remove the displaced device. The 
removal was easily performed in all cases, except for one 
case in which the device was fragmented and extensive pelvic 
adhesions had formed.10 In this case, four subsequent surger-
ies were needed to remove, in order, the right microinsert 
that was found to be perforating through the uterine fundus, 
the left microinsert extending from the endometrial cavity 
through the left myometrium into the peritoneal fat, and, ulti-
mately, the microfragments embedded into tissue adjacent to 
the bladder and into the omentum. Only Kerin et al4 reported 
three cases where Essure was left in situ after having noticed 
that the pelvic organs were healthy and normal. The authors 
did not report later complications for these patients.4
In some cases, the abdominal migration of the device 
is certainly due to uterus or tubal perforation, because the 
perforation is visible at surgical intervention. In the present 
review, only in two cases out of nine did the surgeon detect 
a uterine perforation.5,10 In the remaining cases, although the 
surgeon performed an accurate evaluation of uterus and tubes, 
no signs of perforation or scars were identified (Table 1).   
In such cases, the possibility that migration occurred through 
the fallopian tube cannot be excluded. An alternative hypoth-
esis is that the surgeon may have perforated the tube and the 
insert continued into the abdomen, and the tube just healed 
in the interval before the surgery. However, if the procedure 
is uncomplicated and the recommended number of coils are 
left in the endometrial cavity, the probability of this event 
should be very low. 
Different locations of the device were reported (Table 1). 
In four cases it was adherent to, or entrapped in, the omen-
tum; in two cases it was on peritoneum parietal; in two 
cases it was on the ileum; and in one case it was found in 
the Douglas pouch. Fragments of one device were found 
embedded in the tissue near the bladder and in the omentum.10 
Considering that the Essure microinsert should stimulate 
only benign tissue growth,2 it is not clear why in some cases 
it instead induces inflammation and adhesions, leading to 
major complications.8,10,11 In some cases, hypersensitivity 
reactions to nickel or to other elements of the microinsert 
might be involved in the pathogenesis of this complication, 
as already suggested for orthopedic implant failure.12 Finally, 
in six cases out of eight, the migrated device was the one 
inserted in the left tube (Table 1). Although the sample size 
is too small to draw any conclusions, it can be hypothesized 
that this might be due to the more difficult approach to left 
tubal ostia by right-handed operators.
Conclusion
This review suggests that in the case of a complicated 
procedure, the right placement of both devices should be 
ascertained by adequate imaging and the patient should be 
strictly followed up. Moreover, in the case of occurrence of 
pelvic or abdominal symptomatology, bowel obstruction 
or perforation should be immediately excluded. In the case 
of asymptomatic device displacement detected at 3-month 
follow-up, a laparoscopy should be performed and the device 
should be removed. Bilateral laparoscopic sterilization should 
also be performed. The removed device should be carefully 
inspected and compared with a new, unused one through a 
magnifying glass (because of the small size coils) in order 
to exclude that fragments were left in the abdomen. In cases 
where the original placement was complicated, the oppor-
tunity of removing the contralateral device should also be 
considered. Alternatively, a follow-up of the patient should be 
made necessary. Finally, we advise that during presteriliza-
tion counseling the patient should also be correctly informed 
about the risk of this rare but relevant complication, as well 
as about the surgical interventions that could be required to 
solve it. The rate and the severity of complications of other 
available sterilization methods should also be taken into 
account and made comparable with Essure sterilization for 
an informed choice.
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